Recurrent epithelial ovarian cancer: Pharmacotherapy and novel therapeutics

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2293-2305

  Modesitt, Susan C ^a   Jazaeri, Amir A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Ovarian cancer; Platinum; Recurrence; Secondary debulking

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ALTRETAMINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOSPORIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; EPOTHILONE B; ETOPOSIDE; GEMCITABINE; GESTAGEN; IRINOTECAN; LEDOXANTRONE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM COMPLEX; RALTITREXED; TAMOXIFEN; TAXANE DERIVATIVE; TOPOTECAN; UNINDEXED DRUG; VALSPODAR;

ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; OPTIMAL DRUG DOSE; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY OF LIFE; RECURRENT CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS;

EID: 35548962795     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2293     Document Type: Review

References (115)

1. JEMAL A, SIEGEL R, WARD E et al.: Cancer statistics, 2007. CA Cancer J. Clin. (2007) 57:43-66.
2. EASTON DF, FORD D, BISHOP DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast cancer linkage consortium. Am. J. Hum. Genet. (1995) 56(1):265-271.
3. FORD D, EASTON DE PETO J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am. J. Hum. Genet. (1995) 57(6):1457-1462.
4. FORD D, EASTON DF, STRATTON M et al.: Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am. J. Hum. Genet. (1998) 62(3):676-689.
5. ANTONIOU A, PHAROAH PD, NAROD S et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. (2003) 72(5):1117-1130.
6. ANTONIOU AC, DUROCHER F, SMITH P, SIMARD J, EASTON DF: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res. (2006) 8(1):R3.
7. ANTONIOU AC, PHAROAH PD, NAROD S et al.: Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J. Med. Genetics (2005) 42(7):602-603.
8. OZOLS RF, RUBIN SC, THOMAS GM, ROBBOY SJ: Epithelial ovarian cancer. In: Principles and Practice of Gynecologic Oncology. Hoskins WJ et al. (Eds), Lippincott Williams & Wilkins, Philadelphia (2005):895-903.
9. HAVRILESKY LJ, KULASINGAM SL, MATCHAR DB, MYERS ER: FDG-PET for management of cervical and ovarian cancer. Gynecol. Oncol. (2005) 97(1):183-191.
10. KUROKAWA T, YOSHIDA Y, KAWAHARA K et al.: Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. Ann. Nucl. Med. (2002) 16(7):491-493.
11. SIMCOCK B, NEESHAM D, QUINN M et al.: The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol. (2006) 103(1):271-276.
12. THRALL MM, DELOIA JA, GALLION H, AVRIL N: Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol. Oncol. (2007) 105(1):17-22.
13. BRISTOW RE, DEL CARMEN MG, PANNU HK et al.: Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol. Oncol. (2003) 90(3):519-528.
14. OZOLS RF, OSTCHEGA Y, CURT G, YOUNG RC: High-dose carboplatin in refractory ovarian cancer patients. J. Clin. Oncol. (1987) 5(2):197-201.
15. MARKMAN M, ROTHMAN R, HAKES T et al.: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. (1991) 9(3):389-393.
16. GORE ME, FRYATT I, WILTSHAW E, DAWSON T: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. (1990) 36(2):207-211.
17. CHI DS, MCCAUGHTY K, DIAZ JP et al.: Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer (2006) 106(9):1933-1939.
18. MORRIS M, GERSHENSON DM, WHARTON JT et al.: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol. Oncol. (1989) 34(3):334-338.
19. MUNKARAH A, LEVENBACK C, WOLF JK et al.: Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol. Oncol. (2001) 81(2):237-241.
20. PFISTERER J, HARTER P, CANZLER U et al.: The role of surgery in recurrent ovarian cancer. Int. J. Gynecol. Cancer (2005) 15(Suppl. 3):195-198.
21. HARTER P, BOIS A, HAHMANN M et al.: Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. (2006) 13(12):1702-1710.
22. PARMAR MK, LEDERMANN JA, COLOMBO N et al.: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/ AGO-OVAR-2.2 trial. Lancet (2003) 361(9375):2099-2106.
23. PFISTERER J, PLANTE M, VERGOTE I et al.: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. (2006) 24(29):4699-4707.
24. FERRERO JM, WEBER B, GEAY JF et al.: Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Ann. Oncol. (2007) 18(2):263-268.
25. PECTASIDES D, PSYRRI A, PECTASIDES M, ECONOMOPOULOS T: Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin. Pharmacother. (2006) 7(8):975-987.
26. RAO GG, MILLER DS: Hormonal therapy in epithelial ovarian cancer. Expert Rev. Anticancer Ther. (2006) 6(1):43-47.
27. NICODEMUS CF, BEREK JS: Monoclonal antibody therapy of ovarian cancer. Expert Rev. Anticancer Ther. (2005) 5(1):87-96.
28. MONK BJ, CHOI DC, PUGMIRE G, BURGER RA: Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. (2005) 96(3):902-905.
29. WRIGHT JD, HAGEMANN A, RADER JS et al.: Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. Cancer (2006) 107(1):83-89.
30. COHN DE, VALMADRE S, RESNICK KE et al.: Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. (2006) 102(2):134-139.
31. MONK BJ, HAN E, JOSEPHS-COWAN CA, PUGMIRE G, BURGER RA: Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. (2006) 102(2):140-144.
32. AGHAJANIAN C: The role of bevacizumab in ovarian cancer - an evolving story. Gynecol. Oncol. (2006) 102(2):131-133.
33. BASELGA J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist (2002) 7(Suppl. 4):2-8.
34. BOOKMAN MA, DARCY KM, CLARKE-PEARSON D, BOOTHBY RA, HOROWITZ IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a Phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. (2003) 21(2):283-290.
35. SCHILDER RJ, SILL MW, CHEN X et al.: Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a gynecologic oncology group study. Clin. Cancer Res. (2005) 11(15):5539-5548.
36. GORDON MS, MATEI D, AGHAJANIAN C et al.: Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. (2006) 24(26):4324-4332.
37. TEW KD: TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin. Investig. Drugs (2005) 14(8):1047-1054.
38. KAVANAGH JJ, GERSHENSON DM, CHOI H et al.: Multi-institutional Phase II study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int. J. Gynecol. Cancer (2005) 15(4):593-600.
39. TLK 286: Drugs R D (2004) 5(2):116-118.
40. HAMILTON D, BATIST G: TLK-199 (Telik). IDrugs (2005) 8(8):662-669.
41. BEUMER JH, RADEMAKER-LAKHAI JM, ROSING H et al.: Metabolism of trabectedin (ET-743, Yondelistrade mark) in patients with advanced cancer. Cancer Chemother. Pharmacol. (2007) 59(6):825-837.
42. BEUMER JH, RADEMAKER-LAKHAI JM, ROSING H et al.: Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Investig. N. Drugs (2005) 23(5):429-436.
43. BRANDON EF, MEIJERMAN I, KLIJN JS et al.: In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and Phase II inhibition, and cytochrome P450 induction. Anticancer Drugs (2005) 16(9):935-943.
44. ZELEK L, YOVINE A, BRAIN E et al.: A Phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br. J. Cancer (2006) 94(11):1610-1614.
45. SESSA C, DE BRAUD F, PEROTTI A et al.: Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J. Clin. Oncol. (2005) 23(9):1867-1874.
46. HOFSTETTER B, VUONG V, BROGGINI-TENZER A et al.: Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin. Cancer Res. (2005) 11(4):1588-1596.
47. KAMSTEEG M, RUTHERFORD T, SAPI E et al.: Phenoxodiol - an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene (2003) 22(17):2611-2620.
48. MOR G, FU HH, ALVERO AB: Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr. Opin. Investig. Drugs (2006) 7(6):542-548.
49. WILKINSON E: Phenoxodiol offers hope for ovarian cancer. Lancet Oncol. (2004) 5(4):201.
50. OREGOVOMAB: Anti-CA-125 monoclonal antibody B43.13-AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs in R&D (2006) 7(6):379-383.
51. BEREK JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin. Biol. Ther. (2004) 4(7):1159-1165.
52. BEREK JS, TAYLOR PT, GORDON A et al.: Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. (2004) 22(17):3507-3516.
53. EHLEN TG, HOSKINS PJ, MILLER D et al.: A pilot Phase II study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int. J. Gynecol. Cancer (2005) 15(6):1023-1034.
54. COOPER AL, GREENBERG VL, LANCASTER PS et al.: In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol. Oncol. (2007) 104(3):596-601.
55. LOIZZI V, CHAN JK, OSANN K et al.: Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. (2003) 189(5):1301-1307.
56. GALLION H, CHRISTOPHERSON WA, COLEMAN RL et al.: Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int. J. Gynecol. Cancer (2006) 16(1):194-201.
57. BEREK JS, HACKER NF, LAGASSE LD, NIEBERG RK, ELASHOFF RM: Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet. Gynecol. (1983) 61(2):189-193.
58. JANICKE F, HOLSCHER M, KUHN W et al.: Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer (1992) 70(8):2129-2136.
59. SEGNA RA, DOTTINO PR, MANDELI JP, KONSKER K, COHEN CJ: Secondary cytoreduction for ovarian cancer following cisplatin therapy. J. Clin. Oncol. (1993) 11(3):434-439.
60. VACCARELLO L, RUBIN SC, VLAMIS V et al.: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol. Oncol. (1995) 57(1):61-65.
61. GADDUCCI A, IACCONI P, COSIO S et al.: Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol. Oncol. (2000) 79(3):344-349.
62. EISENKOP SM, FRIEDMAN RL, SPIRTOS NM: The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer (2000) 88(1): 144-153.
63. SCARABELLI C, GALLO A, CARBONE A: Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol. Oncol. (2001) 83(3):504-512.
64. TAY EH, GRANT PT, GEBSKI V, HACKER NF: Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet. Gynecol. (2002) 99(6):1008-1013.
65. ZANG RY, LI ZT, TANG J et al.: Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer (2004) 100(6):1152-1161.
66. GUNGOR M, ORTAC F, ARVAS M et al.: The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol. Oncol. (2005) 97(1):74-79.
67. MATSUMOTO A, HIGUCHI T, YURA S et al.: Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J. Obstet. Gynaecol. Res. (2006) 32(6):580-587.
68. BENEDETTI PANICI P, DE VIVO A, BELLATI F et al.: Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann. Surg. Oncol. (2007) 14(3):1136-1142.
69. SALANI R, SANTILLAN A, ZAHURAK ML et al.: Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer (2007) 109(4):685-691.
70. HAUGE MD, LONG HJ, HARTMANN LC et al.: Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Investig. N. Drugs (1992) 10(4):299-301.
71. MANETTA A, TEWARI K, PODCZASKI ES: Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol. Oncol. (1997) 66(1):20-26.
72. VERGOTE I, HIMMELMANN A, FRANKENDAL B et al.: Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol. Oncol. (1992) 47(3):282-286.
73. MOORE DH, VALEA F, CRUMPLER LS, FOWLER WC Jr: Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma. Gynecol. Oncol. (1993) 51(1):109-112.
74. MARKMAN M, BLESSING JA, MOORE D, BALL H, LENTZ SS: Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a gynecologic oncology group Phase II trial. Gynecol. Oncol. (1998) 69(3):226-229.
75. KAYE SB, PICCART M, AAPRO M, FRANCIS P, KAVANAGH J: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer - an updated overview. Eur. J. Cancer (1997) 33(13):2167-2170.
76. KAVANAGH JJ, KUDELKA AP, DE LEON CG et al.: Phase II study of docetaxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin. Cancer Res. (1996) 2(5):837-842.
77. GORDON AN, GRANAI CO, ROSE PG et al.: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J. Clin. Oncol. (2000) 18(17):3093-3100.
78. GORDON AN, FLEAGLE JT, GUTHRIE D et al.: Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. (2001) 19(14):3312-3322.
79. MUGGIA FM, HAINSWORTH JD, JEFFERS S et al.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. (1997) 15(3):987-993.
80. VERMORKEN JB, KOBIERSKA A, CHEVALLIER B et al.: A Phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC gynecological cancer cooperative group. Ann. Oncol. (2000) 11(8):1035-1040.
81. VERMORKEN JB, KOBIERSKA A, VAN DER BURG ME et al.: High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. Eur. J. Gynaecol. Oncol. (1995) 16(6):433-438.
82. VERMORKEN JB, TEN BOKKEL HUININK WW, KOBIERSKA A et al.: Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma. Oncology (1999) 57(1):10-16.
83. ROSE PG, BLESSING JA, MAYER AR, HOMESLEY HD: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. (1998) 16(2):405-410.
84. FRIEDLANDER M, MILLWARD MJ, BELL D et al.: A Phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. (1998) 9(12):1343-1345.
85. BOOKMAN MA: Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int. J. Gynecol. Cancer (2005) 15(Suppl. 1):12-17.
86. D'AGOSTINO G, AMANT F, BERTELOOT P, SCAMBIA G, VERGOTE I: Phase II study of gemcitabine in recurrent platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. (2003) 88(3):266-269.
87. BODURKA DC, LEVENBACK C, WOLF JK et al.: Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J. Clin. Oncol. (2003) 21(2):291-297.
88. MATSUMOTO K, KATSUMATA N, YAMANAKA Y et al.: The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol. Oncol. (2006) 100(2):412-416.
89. PICCART MJ, GREEN JA, LACAVE AJ et al.: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized Phase II study of the European organization for research and treatment of cancer gynecology group. J. Clin. Oncol. (2000) 18(6):1193-1202.
90. GORE M, TEN BOKKEL HUININK W, CARMICHAEL J et al.: Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J. Clin. Oncol. (2001) 19(7):1893-1900.
91. BOOKMAN MA, MALMSTROM H, BOLIS G et al.: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. (1998) 16(10):3345-3352.
92. SORENSEN P, HOYER M, JAKOBSEN A et al.: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Gynecol. Oncol. (2001) 81(1):58-62.
93. GERSHENSON DM, BURKE TW, MORRIS M et al.: A Phase I study of a daily ×3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol. Oncol. (1998) 70(3):404-409.
94. BURGER RA, DISAIA PJ, ROBERTS JA et al.: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Gynecol. Oncol. (1999) 72(2):148-153.
95. MANETTA A, BLESSING JA, HURTEAU JA: Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a Phase II study of the gynecologic oncology group. Gynecol. Oncol. (1998) 68(1):45-46.
96. PLAXE SC, BLESSING JA, MORGAN MA, CARLSON J: Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a gynecologic oncology group study. Am. J. Clin. Oncol. (2002) 25(1):45-47.
97. FRACASSO PM, BRADY MF, MOORE DH et al.: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. (2001) 19(12):2975-2982.
98. HOFFMAN MA, BLESSING JA, MORGAN M: Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A gynecologic oncology group study. Gynecol. Oncol. (2000) 79(3):463-465.
99. MARKMAN M, BLESSING JA, DEGEEST K et al.: Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A gynecologic oncology group trial. Gynecol. Oncol. (1999) 75(3):444-446.
100. MILLER DS, BLESSING JA, WAGGONER S et al.: Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol. (2005) 96(1):67-71.
101. ROSE PG, BLESSING JA, BALL HG et al.: A Phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol. (2003) 88(2):130-135.
102. FRACASSO PM, BLESSING JA, MORGAN MA, SOOD AK, HOFFMAN JS: Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. J. Clin. Oncol. (2003) 21(15):2856-2859.
103. BREWER CA, BLESSING JA, NAGOURNEY RA, MORGAN M, HANJANI P: Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a Phase II study of the gynecologic oncology group. Gynecol. Oncol. (2006) 103(2):446-450.
104. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a gynecologic oncology group study. Gynecol. Oncol. (2006) 101(3):436-440.
105. MUGGIA FM, BLESSING JA, HOMESLEY HD, SOROSKY J: Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a Phase II study by the gynecologic oncology group. Cancer Chemother. Pharmacol. (1998) 42(1):68-70.
106. MCGUIRE WP, BLESSING JA, BOOKMAN MA, LENTZ SS, DUNTON CJ: Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oncol. (2000) 18(5):1062-1067.
107. PLAXE SC, BLESSING JA, BOOKMAN MA, CREASMAN WT: Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. (2002) 84(1):32-35.
108. HOFFMAN MA, BLESSING JA, NUNEZ ER: A Phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Gynecol. Oncol. (2001) 81(3):433-435.
109. MARKMAN M, BLESSING JA, ALVAREZ RD et al.: Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. (2000) 77(1):112-115.
110. ARMSTRONG DK, BLESSING JA, LOOK KY, SCHILDER R, NUNEZ ER: A randomized Phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: a gynecologic oncology group study. Investig. N. Drugs (2003) 21(3):373-377.
111. HOFFMAN MA, BLESSING JA, LENTZ SS: A Phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Gynecol. Oncol. (2003) 89(1):95-98.
112. MILLER DS, BLESSING JA, LENTZ SS, MCMEEKIN DS: Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study. Cancer (2003) 98(8):1664-1669.
113. GARCIA AA, BLESSING JA, LENZ H-J et al.: Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a gynecologic oncology group study. Gynecol. Oncol. (2005) 96(3):810-817.
114. COVENS A, BLESSING J, BENDER D, MANNEL R, MORGAN M: A Phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol. Oncol. (2006) 100(3):586-590.
115. HURTEAU JA, BLESSING JA, DECESARE SL, CREASMAN WT: Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. (2001) 82(1):7-10.